• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Potential Cardiovascular Risks Associated with Naltrexone-Bupropion Treatment in Overweight Patients [Response to Letter].超重患者使用纳曲酮-安非他酮治疗的潜在心血管风险[对信件的回复]
Drug Des Devel Ther. 2025 Jan 6;19:65-66. doi: 10.2147/DDDT.S512114. eCollection 2025.
2
Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial.纳曲酮-安非他酮对伴有心血管危险因素的超重和肥胖患者主要不良心血管事件的影响：一项随机临床试验。
JAMA. 2016 Mar 8;315(10):990-1004. doi: 10.1001/jama.2016.1558.
3
Potential Cardiovascular Risks Associated with Naltrexone-Bupropion Treatment in Overweight Patients [Letter].超重患者中纳曲酮-安非他酮治疗相关的潜在心血管风险[信函]
Drug Des Devel Ther. 2024 Dec 7;18:5793-5794. doi: 10.2147/DDDT.S509093. eCollection 2024.
4
Combination therapy with naltrexone and bupropion for obesity.纳曲酮与安非他酮联合治疗肥胖症。
Expert Opin Pharmacother. 2011 Aug;12(11):1813-26. doi: 10.1517/14656566.2011.591382. Epub 2011 Jun 21.
5
Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.纳曲酮联合安非他酮对超重和肥胖成年人体重减轻的影响（COR-I）：一项多中心、随机、双盲、安慰剂对照、3 期临床试验。
Lancet. 2010 Aug 21;376(9741):595-605. doi: 10.1016/S0140-6736(10)60888-4. Epub 2010 Jul 29.
6
Use of Contrave, Naltrexone with Bupropion, Bupropion, or Naltrexone and Major Adverse Cardiovascular Events: A Systematic Literature Review.Contrave（纳曲酮与安非他酮复方制剂）、纳曲酮、安非他酮或纳曲酮的使用与主要不良心血管事件：一项系统文献综述
Diabetes Metab Syndr Obes. 2022 Sep 29;15:3049-3067. doi: 10.2147/DMSO.S381652. eCollection 2022.
7
Circulating levels of proglucagon-derived peptides are differentially regulated by the glucagon-like peptide-1 agonist liraglutide and the centrally acting naltrexone/bupropion and can predict future weight loss and metabolic improvements: A 6-month long interventional study.胰高血糖素原衍生肽的循环水平受胰高血糖素样肽-1 激动剂利拉鲁肽和中枢作用的纳曲酮/安非他酮的差异调节，并可预测未来的体重减轻和代谢改善：一项为期 6 个月的干预研究。
Diabetes Obes Metab. 2023 Sep;25(9):2561-2574. doi: 10.1111/dom.15141. Epub 2023 May 29.
8
Naltrexone + bupropion (Mysimba). Too risky for only modest weight loss.纳曲酮 + 安非他酮（Mysimba）。仅为适度减重使用风险过高。
Prescrire Int. 2015 Oct;24(164):229-33.
9
An update on naltrexone/bupropion extended-release in the treatment of obesity.纳曲酮/安非他酮缓释剂治疗肥胖症的最新进展
Expert Opin Pharmacother. 2016 Nov;17(16):2235-2242. doi: 10.1080/14656566.2016.1244527. Epub 2016 Oct 17.
10
Naltrexone ER/Bupropion ER: A Review in Obesity Management.纳曲酮长效/安非他酮长效：肥胖症管理中的应用评价。
Drugs. 2015 Jul;75(11):1269-80. doi: 10.1007/s40265-015-0427-5.

本文引用的文献

1
Potential Cardiovascular Risks Associated with Naltrexone-Bupropion Treatment in Overweight Patients [Letter].超重患者中纳曲酮-安非他酮治疗相关的潜在心血管风险[信函]
Drug Des Devel Ther. 2024 Dec 7;18:5793-5794. doi: 10.2147/DDDT.S509093. eCollection 2024.
2
Safety and Effectiveness of Naltrexone-Bupropion in Korean Adults with Obesity: Post-Marketing Surveillance Study.纳曲酮-安非他酮在韩国肥胖成年人中的安全性和有效性：上市后监测研究。
Drug Des Devel Ther. 2024 Nov 19;18:5255-5268. doi: 10.2147/DDDT.S492913. eCollection 2024.
3
Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes.纳曲酮缓释/安非他酮缓释联合疗法对超重和肥胖2型糖尿病患者体重及血糖参数的影响
Diabetes Care. 2013 Dec;36(12):4022-9. doi: 10.2337/dc13-0234. Epub 2013 Oct 21.
4
A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II).纳曲酮缓释/安非他酮缓释片治疗体重和肥胖相关风险因素的随机、3 期临床试验（COR-II）。
Obesity (Silver Spring). 2013 May;21(5):935-43. doi: 10.1002/oby.20309.
5
Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.纳曲酮联合安非他酮对超重和肥胖成年人体重减轻的影响（COR-I）：一项多中心、随机、双盲、安慰剂对照、3 期临床试验。
Lancet. 2010 Aug 21;376(9741):595-605. doi: 10.1016/S0140-6736(10)60888-4. Epub 2010 Jul 29.
6
Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial.COR-BMOD 试验：作为行为修正辅助治疗的纳曲酮 SR/安非他酮 SR 联合疗法的减肥效果。
Obesity (Silver Spring). 2011 Jan;19(1):110-20. doi: 10.1038/oby.2010.147. Epub 2010 Jun 17.

Potential Cardiovascular Risks Associated with Naltrexone-Bupropion Treatment in Overweight Patients [Response to Letter].

作者信息

Lyu Young Sang, Ahn Hongyup, Hong Sangmo, Park Cheol-Young

机构信息

Division of Endocrinology and Metabolism, Department of Internal Medicine, Chosun University Hospital, Gwangju, Republic of Korea.

Department of Statistics, Dongguk University, Seoul, Republic of Korea.

出版信息

Drug Des Devel Ther. 2025 Jan 6;19:65-66. doi: 10.2147/DDDT.S512114. eCollection 2025.

DOI:10.2147/DDDT.S512114
PMID:39803608
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11721147/
Abstract
摘要